natgillin/translations-raw huggingface dataset:
€63 962 704.38
63.962.704,38 EUR
€65.850
65,850 EUR
€67.310
67,310 EUR
€72.637
72,637 EUR
€72 053 873.45
72.053.873,45 EUR
€78.530
78,530 EUR
€8.000
8,000 EUR
€8.055
8,055 EUR
€8.671
8,671 EUR
€81.308
81,308 EUR
€87.201
87,201 EUR
€9.930
9,930 EUR
€ 15 163
15 163 EUR
€ 1 031
1 031 EUR
€ 25 118
25 118 EUR
€ 26 711
26 711 EUR
€ 2 795
2 795 EUR
€ 42 696
42 696 EUR
€ 6 512
6 512 EUR
€ 6 933
6 933 EUR
€ 9 505
9 505 EUR
≤ 0,5 mg
≤ 0,5 mg
____ From:
____ Iz:
Director of the Representative Office of the Croatian Chamber of Economy in Brussels
Direktorica Predstavništva Hrvatske gospodarske komore u Bruxellesu
Director-General of HUP (Croatian Employers' Association)
Generalni direktor HUP-a (Hrvatskog udruženja poslodavaca)
General Secretary of the Croatian Chamber of Trades and Crafts
Glavna tajnica Hrvatske obrtničke komore
# &gt; 450 msec in male &gt; 470 msec in female (see section 4.4)
# &gt; 450 msek u muškaraca; &gt; 470 msek u žena (vidjeti dio 4.4)
# For adverse reaction not observed in clinical trials, the upper limit of the 95% confidence interval is not higher than 3/X with X representing the total sample size summed up across all relevant clinical trials and studies. a Musculo-skeletal fraction &gt; 3 times the upper limit of the normal range.
# za nuspojave koje nisu zabilježene u kliničkim ispitivanjima, gornja granica 95% intervala pouzdanosti nije viša od 3/X gdje X predstavlja ukupni uzorak svih relevantnih kliničkih ispitivanja. a Porast vrijednosti mišićno-koštane frakcije &gt; 3 puta iznad gornje granice normalnog raspona.
# p &lt; 0.05 dulaglutide treatment group compared to liraglutide.
# p &lt; 0,05 za skupinu liječenu dulaglutidom u usporedbi s liraglutidom
# p &lt; 0.05, ## p &lt; 0.001 dulaglutide treatment group compared to insulin glargine
# p &lt; 0,05, ## p &lt; 0,001 za skupinu liječenu dulaglutidom u usporedbi s inzulinom glarginom
# p &lt; 0.05, ## p &lt; 0.001 dulaglutide treatment group compared to metformin
# p &lt; 0,05, ## p &lt; 0,001 za skupinu liječenu dulaglutidom u usporedbi s metforminom
# p &lt; 0.05, ##p &lt; 0.001 dulaglutide treatment group compared to exenatide
# p &lt; 0,05, ##p &lt; 0,001 za skupinu liječenu dulaglutidom u usporedbi s eksenatidom
# p-value (vs. lamivudine) &lt; 0.01 (stratified Cochran-Mantel-Haenszel test)
# p-vrijednost (u odnosu na lamivudin) &lt; 0.01 (stratificirani Cochran-Mantel-Haenszel test)
# Predicted difference of response rates (95% CI) for the week 48 analysis: 1.6% (-2.2%; 5.3%) and for the week 96 analysis: -0.4% (-4.6%; 3.8%); both p-value &lt; 0.0001 (non-inferiority at 12% margin) from logistic regression model, including stratification factors and study.
# Predviđena razlika u stopama odgovora (95% CI) za analizu u 48. tjednu: 1,6% (-2,2%; 5,3%) i za analizu u 96. tjednu: -0,4% (-4,6%; 3,8%); p-vrijednost &lt; 0,0001 (neinferiornost uz marginu od 12%) prema modelu logističke regresije, uključujući stratifikacijske čimbenike i ispitivanje.
## p &lt; 0.001 dulaglutide treatment group compared to sitagliptin
## p &lt; 0,001 za skupinu liječenu dulaglutidom u usporedbi sa sitagliptinom
#with a higher incidence (difference of ≥ 2% between the treatment arms).
#s većom incidencijom (razlika &gt; 2% između liječenih skupina).
&amp; “Flu-like symptom complex” denotes flu syndrome and/or a combination of at least two adverse events from fever, chills, myalgia, malaise, sweating.
&amp; „Kompleks simptoma nalik gripi“ označava sindrom gripe i/ili kombinaciju najmanje dva štetna događaja od vrućice, zimice, bolova u mišićima, malaksalosti, znojenja.
&amp; “Flu-like symptom complex” denotes flu syndrome and/or a combination of at least two AEs from fever, chills, myalgia, malaise, sweating.
&amp; „Kompleks simptoma nalik gripi“ označava sindrom gripe i/ili kombinaciju najmanje dva štetna događaja između vrućice, zimice, mialgije, malaksalosti, znojenja.
(0.094, 0.359) (p &lt; 0.0001)
(0,094; 0,359) (p &lt; 0,0001)
(0.155, 0.388) (p &lt; 0.0001)
(0,155; 0,388) (p &lt; 0,0001)
(12.0, 23.9)
18,0% p &lt; 0,001 (12,0; 23,9)
(13.0, 25.6)
19,3% p &lt; 0,001 (13,0; 25,6)
(4.3, 16.8)
10,6% p &lt; 0,001 (4,3; 16,8)
(6.2, 18.1)
12,1% p &lt; 0,001 (6,2; 18,1)
(60.6, 69.7) (p &lt; 0.0001)
(60,6, 69,7) (p &lt; 0,0001)
(66, 154) (p &lt; 0.0001)
(66, 154) (p &lt; 0,0001)
(70.2% vs 44.5%) p &lt; 0.0001
(70,2% vs 44,5%) p &lt; 0,0001
(72.9, 81.60) (p &lt; 0.0001)
(72,9, 81,6) (p &lt; 0,0001)
(73, 160) (p &lt; 0.0001)
(73, 160) (p &lt; 0,0001)
( &lt; 0.001)
&gt; 54 tjedna ( &lt; 0,001)
( &lt; 0.5 x 109/L) or thrombocytopenia ( &lt; 25  109/L) that results in more than 1
( &lt; 0,5 x 109/L) ili thrombocitopenije ( &lt; 25  109/L) koji rezultira odgađanjem početka idućeg ciklusa za više od tjedan dana
( &lt; 25,000/mm3)
( &lt; 25 000/mm3)
(CLcr &lt; 30 mL/min, requiring dialysis)
(30  CLcr &lt; 50 mL/min)
(CLcr &lt; 30 mL/min, requiring dialysis)
Terminalni stadij bubrežne bolesti (CLcr &lt; 30 mL/min, potrebna je dijaliza)
(cognitively normal &amp; clinical AD)
(normalna kognitivna funkcija i
(cognitively normal &amp; MCI)
(normalna kognitivna funkcija i
(combined rosuvastatin, simvastatin, &amp; atorvastatin groups)
(skupine koje su primale kombinaciju s rosuvastatinom, simvastatinom i atorvastatinom)
(Common, ≥1/100 to &lt; 1/10)
(Često, ≥1/100 do &lt; 1/10)
(p-value  )
(p-vrijednost &lt; 0,0001)
(S)-Methoprene and Amitraz: Dermal absorption is very low and all plasma concentrations were below the limit of quantification (10 ng/ml) for (S)-methoprene and were undetectable for amitraz ( &lt; 0.75 ng/ml) in most samples.
(S)-Metopren (mg) i Amitraz: apsorpcija kroz kožu je vrlo niska i sve koncentracije u krvi bile su ispod kvantifikacijske granice (10 ng/ml) za (S)-metopren, a za amitraz ( &lt; 0,75 ng/ml) u većini uzoraka nisu se mogle otkriti.
(sunrise; morning dose) (sun; daytime dose) and (moon; evening dose).
(svitanje; jutarnja doza) (sunce; dnevna doza) i (mjesec; večernja doza).
(≤600,000 IU/ml)
Veliko virusno opterećenje ( &gt; 600 000 IU/ml)
(≥ 1/100 to &lt; 1/10)
(≥ 1/100 do &lt; 1/10)
(≥ 1/1000 to &lt; 1/100)
(≥ 1/1000 i &lt; 1/100);
(≥ 12 to &lt; 17 years old) who participated in Study 206.
13 adolescenata s CF (u dobi ≥ 12 do &lt; 17 godina) koji su sudjelovali u Ispitivanju 206.
(≥1/1,000 to &lt; 1/100)
Manje često (≥1/1000 i &lt; 1/100)
(≥1/10,000 to
Rijetko (≥1/10 000 i &lt; 1/1000)
(≥1/100 to &lt; 1/10)
(≥ 1/100 do &lt; 1/10)
+ frequency of acquired resistance &gt; 50 % in some Member States
+ Učestalost stečene rezistencije je &gt; 50% u nekim državama članicama.
0 - 12 months
&gt; 3 mjeseca do 12 mjeseci
0% ( &gt; 3.4 x ULN)
0% ( &gt; 3,4 x GGN)
0- &lt; 6 years N=24
0- &lt; 6 godina N=24
0.08 ± 0.03 ; 0.01 to 0.15; &lt; 0.0001
0,08 ± 0,03 ; 0,01 do 0,15; &lt; 0,0001
0.1 (-0.3, 0.7) in patients receiving emtricitabine+tenofovir alafenamide and 0.0 (-0.4, 0.5) in patients receiving emtricitabine+tenofovir disoproxil fumarate (p &lt; 0.001 for the difference between treatment groups).
96. tjednu bio je 0,1 (-0,3; 0,7) u bolesnika koji su primali emtricitabin+tenofoviralafenamid i 0,0 (-0,4; 0,5) u bolesnika koji su primali emtricitabin+tenofovirdizoproksilfumarat (p &lt; 0,001 za razliku između liječenih skupina).
0.1% of patients receiving Taltz developed a neutrophil count &lt; 1000 cells/mm3.
U 0,1% bolesnika koji su primali Taltz broj neutrofila pao je na &lt; 1000 stanica/mm3.
0.25-0.49; p &lt; 0.00001), moreover, pre-planned subgroup analysis by BRCA-mutation status identified patients with BRCA-mutated ovarian cancer (n=136, 51.3%) as the subgroup that derived the greatest clinical benefit from olaparib maintenance monotherapy.
Osim toga, unaprijed planirana analiza podskupina prema statusu mutacije BRCA gena pokazala je da su bolesnice oboljele od karcinoma jajnika s mutacijom BRCA gena (n=136; 51,3%) činile podskupinu koja je imala najveću kliničku korist od monoterapije održavanja olaparibom.
0.3% ( &gt; 5.0 x ULN)
0,3% ( &gt; 5,0 x GGN)
0.3% of patients receiving co-administration had clinically relevant increases in creatinine to values &gt; 200 µmol/L.
0,3% bolesnika koji su istodobno primali navedene lijekove imalo je klinički značajna povišenja kreatinina do vrijednosti &gt; 200 µmol/l.
0.3% of patients receiving co-administration had clinically relevant increases in creatinine to values &gt; 200 µmol/l.
0,3% bolesnika koji su istodobno primali navedene lijekove imalo je klinički značajna povišenja kreatinina do vrijednosti &gt; 200 µmol/l.
0.32 l/h/kg, with predominantly renal clearance ( &gt; 70 %) via the organic cationic transport system.
0,32 l/h/kg, i odvija se pretežno renalnim klirensom ( &gt; 70%), putem organskog kationskog transportnog sustava.
0.350 [0.287, 0.426], p &lt; 0.001
0,350 [0,287; 0,426], p &lt; 0,001
0.49 (0.37,0.65), p &lt; 0.0001
0,49 (0,37, 0,65), p &lt; 0,0001
0.51 (0.41, 0.62), p &lt; 0.0001
0,51 (0,41; 0,62); p &lt; 0,0001
0.518 (p-value  0.0001)
0,518 (p-vrijednost &lt; 0,0001)
0.58 (0.45, 0.74), p &lt; 0.0001
0,58 (0,45; 0,74); p &lt; 0,0001
0.63); p &lt; 0.0001], and other types of bleeding (Table 6).
(95% CI): 0,47 (0,34, 0,63); p &lt; 0,0001] i drugih vrsta krvarenja (tablica 6).
0.66 [0.54, 0.81] (p-value5 &lt; 0.0001)
0,66 [0,54; 0,81] (p-vrijednost5 &lt; 0,0001)
0.68 (0.59, 0.78) (p-value &lt; 0.0001)
0,68 (0,59; 0,78) (p-vrijednost &lt; 0,0001)
0.78h, 95% CI [-1.18, -0.39], p=0.0001. The mean total daily decrease in the OFF time was similar in the entacapone group (-0.80h, 95% CI [-1.20, -0.41], p &lt; 0.0001) to that observed in the rasagiline 1 mg group.
Srednje ukupno dnevno smanjenje u OFF vremenu u entakapon skupini (-0,80 h, 95 % CI [-1,20, -0,41], p &lt; 0,0001) bilo je slično onom opaženom u razagilin 1 mg skupini.
0.89 (0.70, 1.13) p-value &lt; 0.0001 (non-inferiority)
0,89 (0,70, 1,13) p-vrijednost &lt; 0,0001 (neinferiornost)
0.9 months (p &lt; 0.000001).
4,8 mjeseci naspram 0,9 mjeseci (p &lt; 0,000001).
0− &lt; 6 years
0 − &lt; 6 godina
1 Adverse events occurring with frequencies &lt; 5 % were medically assessed and it was shown that these cases are consistent with the well-established safety profile of zoledronic acid (see section 4.8)
1 Nuspojave koje nastaju učestalošću &lt; 5% bile su medicinski procijenjene i pokazalo se da su u skladu s dobro utvrđenim sigurnosnim profilom zoledronatne kiseline (vidjeti dio 4.8).
1 Adverse events occurring with frequencies &lt; 5% were medically assessed and it was shown that these cases are consistent with the well established safety profile of zoledronic acid (see section 4.8)
1 Nuspojave koje nastaju učestalošću &lt; 5% bile su medicinski procijenjene i pokazalo se da su u skladu s dobro utvrđenim sigurnosnim profilom zoledronatne kiseline (vidjeti dio 4.8).
1 Adverse events occurring with frequencies &lt; 5% were medically assessed and it was shown that these cases are consistent with the well established safety profile of zoledronic acid (see section 4.8)
1 Štetni događaji koji nastaju s učestalošću &lt; 5% bili su medicinski procijenjeni i pokazalo se da su ti slučajevi skladu s dobro utvrđenim sigurnosnim profilom zoledronatne kiseline (vidjeti dio 4.8).
1 Adverse events occurring with frequencies &lt; 5% were medically assessed and it was shown that these cases are consistent with the well established safety profile of zoledronic acid (see section 4.8)
1 Štetni događaji koji nastaju s učestalošću &lt; 5% bili su medicinski procijenjeni i pokazalo se da su ti slučajevi u skladu s dobro utvrđenim sigurnosnim profilom zoledronatne kiseline (vidjeti dio 4.8).
1 Adverse events occurring with frequencies &lt; 5% were medically assessed and it was shown that these cases are consistent with the well established safety profile of zoledronic acid (see section 4.8)
1 Štetni događaji koji nastaju s učestalošću &lt; 5% bili su medicinski procijenjeni i pokazalo se da su u skladu s dobro utvrđenim sigurnosnim profilom zoledronatne kiseline (vidjeti dio 4.8).
1 Adverse events occurring with frequencies &lt; 5% were medically assessed and it was shown that these cases are consistent with the well established safety profile of Zometa (see section 4.8)
1 Štetni događaji koji nastaju s učestalošću &lt; 5% bili su medicinski procijenjeni i pokazalo se da su u skladu s dobro utvrđenim sigurnosnim profilom Zomete (vidjeti dio 4.8)
1 Adverse events occurring with frequencies &lt; 5% were medically assessed and it was shown that these cases are consistent with the well-established safety profile of zoledronic acid (see section 4.8)
1 Nuspojave koje nastaju učestalošću &lt; 5% bile su medicinski procijenjene i pokazalo se da su u skladu s dobro utvrđenim sigurnosnim profilom zoledronatne kiseline (vidjeti dio 4.8).
1 Cochran-Mantel-Haenszel (CMH) test p-value for response rate (vs. imatinib 400 mg) &lt; 0.0001
1 P-vrijednost na temelju Cochran-Mantel-Haenszelovog (CMH) testa za stopu odgovora (u odnosu na imatinib 400 mg) &lt; 0,0001
1 Difference is “≤5 ng/ml” minus “ &gt; 5 ng/ml”
1 Razlika je „≤5 ng/ml” minus „ &gt; 5 ng/ml”
1 Haematological response criteria (all responses to be confirmed after &gt; 4weeks):
1Kriteriji hematološkog odgovora (svi se odgovori moraju potvrditi nakon ≥4 tjedna):
1 p-values &lt; 0.0001
1p-vrijednosti  0,0001
1 Patients with ≥ one dose of study drug with evaluable baseline liver biopsies and baseline Knodell Histological Activity Index (HAI) score &gt; 3.
1 Bolesnici koji su uzeli ≥1 doze ispitivanog lijeka, s početnom biopsijom jetre koja se mogla procijeniti i početnim indeksom histološke aktivnosti po Knodellu &gt; 3.
1 Progression of disability was defined as at least a 1.0 point increase on the EDSS from a baseline EDSS &gt; =1.0 sustained for 12 or 24 weeks or at least a 1.5 point increase on the EDSS from a baseline EDSS =0 sustained for 12 or 24 weeks.
1 Progresija onesposobljenosti određena je kao povećanje za najmanje 1,0 vrijednost EDSS od početne vrijednosti EDSS &gt; =1,0 u trajanju barem 12 ili 24 tjedna ili kao povećanje za najmanje 1,5 vrijednosti EDSS od početne vrijednosti EDSS =0 u trajanju barem 12 ili 24 tjedna.
1 results from subjects receiving either 100 mg QD (n=10: patients with serum creatinine &gt; 1.5 and 2.0 mg/dL) or 300 mg QD (n=509) were pooled for analyses.
1 rezultati ispitanika koji su primali 100 mg jednom dnevno (n=10: bolesnici s kreatininom u serumu &gt; 1,5 i 2,0 mg/dl) ili 300 mg jednom dnevno (n=509) su zbrojeni za potrebe analize.
1 to &lt; 2 years
1 do &lt; 2 godine
1 to &lt; 6 months
1do &lt; 6 mjeseci
1 to &lt; 6 years (N=12)
1 do &lt; 6 godina (N=12)
1 While the exact incidence of eosinophilic pneumonia associated with daptomycin is unknown, to date the reporting rate of spontaneous reports is very low ( &lt; 1/10,000).
1 Iako je točna incidencija eozinofilne pneumonije povezane s daptomicinom nepoznata, do sada je stopa prijavljivanja spontanih izvješća bila vrlo niska ( &lt; 1/10 000).
1 year to &lt; 5 years
od 1 godine do &lt; 5 godina
1 yr &lt; 5 yrs
1 god &lt; 5 god
1% of patients receiving 75 mg and 2% of patients receiving 100 mg discontinued treatment or temporarily suspended dosing secondary to constipation, respectively, compared to &lt; 1% of patients treated with placebo.
1% bolesnika koji su primali 75 mg i 2% bolesnika koji su primali 100 mg prekinulo je liječenje ili je privremeno prekinulo doziranje radi konstipacije, u usporedbi sa &lt; 1% bolesnika koji su primali placebo.
1), time from diagnosis to randomisation ( &lt; 1 year vs. ≥1 year), tumour MET status (high vs. low vs. unknown), bone metastases (absence vs. presence), visceral metastases (absence vs. presence), visceral and bone metastases (absence vs. presence), number of prior VEGFR-TKIs (1 vs. ≥2), duration of first VEGFR-TKI (≤6 months vs. &gt; 6 months).
1), vremenu od dijagnoze do randomizacije ( &lt; 1 godine vs. ≥1 godine), MET statusu tumora (visok vs. nizak vs. nepoznat), koštanim metastazama (odsutnost vs. prisutnost), visceralnim metastazama (odsutnost vs. prisutnost), visceralnim i koštanim metastazama (odsutnost vs. prisutnost), broju prethodnih VEGFR-TKI-a (1 vs. ≥2), trajanju primjene prvog VEGFR-TKI (≤6 mjeseci vs. &gt; 6 mjeseci).
1, rue de la Vierge, Ambarès &amp; Lagrave, F-33565 Carbon Blanc cedex, France
1, rue de la Vierge, Ambarès &amp; Lagrave, F-33565 Carbon Blanc cedex, Francuska
1, rue de la Vierge, Ambarès &amp; Lagrave, F-33565 Carbon Blanc cedex, France or
1, rue de la Vierge, Ambarès &amp; Lagrave, F-33565 Carbon Blanc cedex, Francuska ili
1,216 antiretroviral-therapy naïve patients with plasma HIV-1 RNA &gt; 5,000 copies/ml at baseline were assigned to nevirapine 400 mg once daily, nevirapine 200 mg twice daily, efavirenz 600 mg once daily, or nevirapine (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine for 48 weeks.
1216 bolesnika prethodno neliječenih antiretrovirusnim lijekovima s HIV-1 RNK u plazmi &gt; 5000 kopija/ml primali su nevirapin 400 mg jednom dnevno, nevirapin 200 mg dvaput dnevno, efavirenz 600 mg jednom dnevno ili nevirapin (400 mg) i efavirenz (800 mg) jednom dnevno, plus stavudin i lamivudin tijekom 48 tjedana.
1,216 antiretroviral-therapy naïve patients with plasma HIV-1 RNA &gt; 5,000 copies/ml at baseline were assigned to Viramune 400 mg once daily, Viramune 200 mg twice daily, efavirenz 600 mg once daily, or Viramune (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine for 48 weeks.
1 216 bolesnika prethodno neliječenih antiretrovirusnim lijekovima s HIV-1 RNK u plazmi &gt; 5000 kopija/ml primali su Viramune 400 mg jednom dnevno, Viramune 200 mg dvaput dnevno, efavirenz 600 mg jednom dnevno ili Viramune (400 mg) i efavirenz (800 mg) jednom dnevno, plus stavudin i lamivudin tijekom 48 tjedana.
1,216 antiretroviral-therapy naïve patients with plasma HIV-1 RNA &gt; 5,000 copies/ml at baseline were assigned to Viramune 400 mg once daily, Viramune 200 mg twice daily, efavirenz 600 mg once daily, or Viramune (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine for 48 weeks.
1216 bolesnika prethodno neliječenih antiretrovirusnim lijekovima s HIV-1 RNK u plazmi &gt; 5000 kopija/ml primali su Viramune 400 mg jednom dnevno, Viramune 200 mg dvaput dnevno, efavirenz 600 mg jednom dnevno ili Viramune (400 mg) i efavirenz (800 mg) jednom dnevno, plus stavudin i lamivudin tijekom 48 tjedana.
1.02)]; CrCL ≥ 80 mL/min [HR (95% CI): 1.15 (0.95, 1.40)].
&lt; 80 ml/min [HR (95% CI): 0,87 (0,75, 1,02)]; CrCL ≥ 80 ml/min [HR (95% CI): 1,15 (0,95, 1,40)].
1.1, p0.001).
1,1%, p &lt; 0,001).
1.21
1 a.
1.5xULN &lt; transaminases  2.5ULN and/or ULN &lt; GGT  5ULN ].
[ GGN (gornja granica normale) &lt; bilirubin  1,5GGN i/ili 1,5xGGN &lt; transaminaze
1.62 (1.32, 1.99) , P &lt; 0.0001
Vareniklin naspram NRT-a 1,74 (1,43, 2,10) , P &lt; 0,0001 1,62 (1,32, 1,99) , P &lt; 0,0001
1.72 p = 0.0062
1,72 p &lt; 0,0062
1.74 (1.41, 2.14) , P &lt; 0.0001
2,26 (1,80, 2,85) , P &lt; 0,0001 1,87 (1,46, 2,39) , P &lt; 0,0001
1.74 (1.43, 2.10) , P &lt; 0.0001
1,77 (1,46, 2,14) , P &lt; 0,0001 1,74 (1,41, 2,14) , P &lt; 0,0001
1.77 (1.46, 2.14) , P &lt; 0.0001
4,00 (3,20, 5,00), P &lt; 0,0001 3,24 (2,56, 4,11) , P &lt; 0,0001
10 kg to &lt; 15 kg N=5
10 kg do &lt; 15 kg n=5
10 P = .0006
25%; P &lt; 0,0001
10 to &lt; 12
10 do &lt; 12
10 to &lt; 20
10 do &lt; 20
10 to &lt; 20 kg
10 do &lt; 20 kg
10 to &lt; 20 kg
od 10 do &lt; 20 kg
10 years to &lt; 18 years
od 10 godina do &lt; 18 godina
10 yrs &lt; 18 yrs
10 god &lt; 18 god
10.0%
&gt; 38°C
10.6% p &lt; 0.001 (4.3, 16.8)
10,6% p &lt; 0,001 (4,3; 16,8)
100 to &lt; 200 cells/mm3
100 do &lt; 200 stanica
11%; P &lt; .0001
11%; P &lt; 0,0001
11.7% p &lt; 0.001 (4.9, 18.4)
11,7% p &lt; 0,001 (4,9; 18,4)
12 to &lt; 14
12 do &lt; 14
12 to &lt; 18 years
12 do &lt; 18 godina
12 to &lt; 18 years ETR
12 do &lt; 18 godina ETR
12 to &lt; 24 months
12 do &lt; 24 mjeseci
12 to &lt; 18 years (12, 17)
od 12 do &lt; 18 godina (12, 17)
12 to &lt; 18 years (N=8)
12 do &lt; 18 godina (N=8)
12- &lt; 18 years N=23
12- &lt; 18 godina
12- &lt; 18 years N=23
12- &lt; 18 godina N=23
12.1% p &lt; 0.001 (6.2, 18.1)
12,1% p &lt; 0,001 (6,2; 18,1)
12.3L/min p &lt; 0.001 (5.8, 18.8)
12,3 l/min p &lt; 0,001 (5,8; 18,8)
13 to &lt; 15
13 do &lt; 15
13 to &lt; 24
13 do &lt; 24
14 Observed for fasting normal levels at baseline ( &lt; 1.016 mmol/l) which increased to high (≥ 1.467 mmol/l) and changes in fasting triglycerides from borderline at baseline (≥ 1.016 mmol/l- &lt; 1.467 mmol/l) to high (≥ 1.467 mmol/l).
14 Uočeno za normalne početne razine triglicerida natašte ( &lt; 1,016 mmol/l) koje su porasle na visoke razine (≥ 1,467 mmol/l) i promjene vrijednosti triglicerida natašte od početnih graničnih vrijednosti (≥ 1,016 mmol/l- &lt; 1,467 mmol/l) do visokih vrijednosti (≥ 1,467 mmol/l).
14 to &lt; 17
14 do &lt; 17
14.6L/min p &lt; 0.001 (7.9, 21.3)
14,6 l/min p &lt; 0,001 (7,9; 21,3)
14.8 (14.1; 15.4) 10.9 (10.2; 12.0) p-valuea &lt; 0.0001
14,8 (14,1; 15,4) 10,9 (10,2; 12,0)
140 mg once daily n = 304 All grades Grade 3/4
140 mg jedanput dnevno n = 304 Svi stupnjevi 3./4. stupanj
15 Changes in total fasting cholesterol levels from normal at baseline ( &lt; 4.39 mmol/l) to high (≥ 5.17 mmol/l) were observed commonly.
15 Promjena ukupnog kolesterola natašte od normalnih vrijednosti na početku ( &lt; 4,39 mmol/l) do visokih (≥ 5,17 mmol/l) bila je česta.
15 Changes in total fasting cholesterol levels from normal at baseline ( &lt; 4.39 mmol/l) to high (≥ 5.17 mmol/l) were observed commonly.
15 Često su uočene promjene ukupnog kolesterola natašte od normalnih početnih vrijednosti ( &lt; 4,39 mmol/l) do visokih vrijednosti (≥ 5,17 mmol/l).
15 kg to &lt; 20 kg N=16
15 kg do &lt; 20 kg n=16
15 to &lt; 20
15 do &lt; 20
15 to &lt; 30
15 do &lt; 30
150 children were followed-up for three years without booster, additional 150 children received a booster after 1 year (0.25 ml if aged &lt; 3 years at time of the booster, 0.5 ml if aged 3 years and above) and were followed-up for further two years.
Praćeno je 150 djece u razdoblju od tri godine bez docjepljivanja, dodatnih 150 djece docijepljeno je nakon 1 godine (0,25 ml za dob &lt; 3 godine u vrijeme docjepljivanja; 0,5 ml za dob 3 ili više godina) te je praćeno sljedeće dvije godine.
150 mg for patients with body weight &gt; 40 kg
150 mg za bolesnike s tjelesnom težinom &gt; 40 kg
150 to &lt; 300 cells/L
150 do &lt; 300 stanica/l
15Changes in total fasting cholesterol levels from normal at baseline ( &lt; 4.39 mmol/l) to high (≥ 5.17 mmol/l) were observed commonly.
15 Često su uočene promjene ukupnog kolesterola natašte od normalnih početnih vrijednosti ( &lt; 4,39 mmol/l) do visokih vrijednosti (≥ 5,17 mmol/l).
16% of patients had &lt; 6 bone metastases, 44% of patients had between 6 and 20 bone metastases, 40% of patients had more than 20 bone metastases or superscan.
16% bolesnika imalo je &lt; 6 koštanih metastaza, 44% bolesnika imalo je između 6 i 20 koštanih metastaza, 40% bolesnika imalo je više od 20 koštanih metastaza ili “superscan”.
16.7% (Mayo regimen); p &lt; 0.0002. The median time to progression was 140 days (capecitabine) vs.
Medijan vremena do progresije bolesti iznosio je 140 dana (kapecitabin) u odnosu na 144 dana (Mayo protokol).
17 to &lt; 19
17 do &lt; 19
178 of the 580 enrolled patients (30.7%) were defined as having severe disease (CDAI score &gt; 300 and concomitant corticosteroid and/or immunosuppressants) corresponding to the population defined in the indication (see section 4.1).
580 uključenih bolesnika 178 (30,7%) je imalo težak oblik bolesti (CDAI rezultat &gt; 300 uz istodobno uzimanje kortikosteroida i/ili imunosupresiva), što je odgovaralo populaciji definiranoj u indikaciji (vidjeti dio 4.1).
178 of the 580 enrolled patients (30.7%) were defined as having severe disease (CDAI score &gt; 300 and concomitant corticosteroid and/or immunosuppressants) corresponding to the population defined in the indication (see section 4.1).
Od 580 uključenih bolesnika 178 (30,7%) je imalo težak oblik bolesti (CDAI rezultat &gt; 300 uz istodobno uzimanje kortikosteroida i/ili imunosupresiva), što je odgovaralo populaciji definiranoj u indikaciji (vidjeti dio 4.1).
18.0% p &lt; 0.001 (12.0, 23.9)
18,0% p &lt; 0,001 (12,0; 23,9)
19 to &lt; 22
19 do &lt; 22
19.3% p &lt; 0.001 (13.0, 25.6)
19,3% p &lt; 0,001 (13,0; 25,6)